Clinical trials: Gastric Cancer, completed
Gastric Cancer
Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from gastric cancer patients using advanced mass spectrometry detection technology, in conjunction with both broad-spectrum and…
- Trial name
- NCT06109805
- Testing
- Gastric cancer
- Where
- 4 sites in China
- Volunteers
- 1,706 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Gastrointestinal Cancer
Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer
In this study, researchers wanted to learn more about the effect of Aspirin taken as low dose (75 - 300 mg) in preventing stomach, colorectal and esophagus cancer.
- Trial name
- ENgAGE-HK (NCT04081831)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- Hong Kong
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Advanced Gastric Cancer
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate, nab-paclitaxel and S-1
- Trial name
- NCT04195828
- Testing
- Camrelizumab, Apatinib Mesylate, nab-paclitaxel
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Fujian Medical University
Gastric Cancers
Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers
Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes.
- Trial name
- NCT06686966
- Testing
- gastric cancer
- Volunteers
- 3,400 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Gastric Dysplasia, Neoplasia
Radiofrequency Ablation for the Treatment of Gastric Dysplasia
The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma.
- Trial name
- NCT01523912
- Testing
- Radiofrequency ablation of dysplastic mucosa (HALO)
- Where
- Portugal
- Volunteers
- 10 people
- Sponsor
- Hospital Sao Joao
Gastric Cancer
Laparoscopic Versus Open Gastrectomy for Gastric Cancer
This is the first randomized controlled trial comparing laparoscopic and open gastrectomy for resectable gastric cancer in a Western population.
- Trial name
- LOGICA (NCT02248519)
- Testing
- Open Gastrectomy, Laparoscopic Gastrectomy
- Where
- 10 sites in Netherlands
- Volunteers
- 210 people
- Sponsor
- UMC Utrecht
Stomach Neoplasms
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
The purpose of this study is to assess the effectiveness, safety, and actual treatment status of first-line nivolumab plus chemotherapy in participants with untreated advanced / recurrent gastric cancer in a Japanese real-world…
- Trial name
- G-KNIGHT (NCT05334719)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Benign Neoplasm of Stomach, Malignant Neoplasm of Stomach
Surgicel® Fibrillar for Delayed Bleeding After ESD
The aim of this study is to assess the effect of Surgicel® Fibrillar as adjuvant treatment to H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors
- Trial name
- NCT01758965
- Testing
- PPI, H2RA and surgicel
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Soonchunhyang University Hospital
Neoplasms, Gastrointestinal Tract
Study of GSK1363089 in Metastatic Gastric Cancer
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
- Trial name
- NCT00725712
- Testing
- GSK1363089 (formerly XL880)
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- GlaxoSmithKline
Malignancies, Stomach Cancer
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can predict the efficacy and adverse events of apatinib in patients with malignancies.
- Conditions
- Malignancies, Stomach Cancer, Non-small Cell Lung Cancer, Esophageal Cancer
- Trial name
- NCT03384511
- Testing
- Apatinib
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Cancers With HER2 Expression
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein
In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor Receptor 2) and cannot be cured by…
- Trial name
- NCT04147819
- Testing
- BAY2701439
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Bayer
Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
Background: Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g.
- Conditions
- Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase, Gastric Cancer With Hepatic Metastase, Breast Cancer With Hepatic Metastase
- Trial name
- NCT01437007
- Testing
- TKM-080301
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD…
- Trial name
- NCT00215995
- Testing
- Cisplatin, Irinotecan, ZD 1839
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
This is an open label phase 1/1b study of Rilotumumab in Japanese subjects with advanced solid tumors or metastatic gastric esphagogastric (GEJ) adenocarcinoma.
- Conditions
- Part 1- Advanced Solid Tumors, Part 2- Advanced or Metastatic Gastric Cancer, Part 2- Advanced or Metastatic GEJ
- Trial name
- NCT01791374
- Testing
- Rilotumumab
- Where
- 7 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Amgen
Gastric Neoplasm
A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to evaluate survival benefit of TS-1 plus cisplatin as a neoadjuvant chemotherapy in gastric cancer patient with resectable type 4 (linitis plastica type) and large type 3 tumor in comparison with surgery…
- Trial name
- NCT00252161
- Testing
- Gastrectomy with more than D2 dissection, Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
- Where
- 35 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Haruhiko Fukuda
H.Pylori, Gastric Cancer
Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study
Background: Helicobacter pylori is a major risk factor for gastric cancer, yet in many developing countries, including Bhutan where gastric cancer incidence is high, access to screening and eradication is limited.
- Conditions
- H.Pylori, Gastric Cancer, H Pylori Eradication
- Trial name
- NCT07211880
- Testing
- Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin, Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer), Urea Breath Test for the prevalence of H pylori
- Where
- Bhutan
- Volunteers
- 1,043 people, healthy volunteers welcome
- Sponsor
- Zero Helicobacter IGAN Network
Gastric Cancer
A Study of Telatinib in Combination With Chemotherapy in Subjects With Advanced Gastric Cancer
The objectives of this study are to evaluate the anti-tumor activity, safety, and tolerability of telatinib when used in combination with chemotherapy (capecitabine and cisplatin) as first-line therapy in subjects with advanced…
- Trial name
- NCT00952497
- Testing
- Cisplatin, Capecitabine, Telatinib
- Where
- 11 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- ACT Biotech, Inc
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Stomach Neoplasms
Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy
The purpose of this study is to determine whether premedication with Simethicone or Simethicone plus N-acetylcysteine are effective improving visibility during Upper endoscopy compared with use of water or no preparation.
- Trial name
- PRUE (NCT01653171)
- Testing
- Simethicone, N-acetylcysteine 500 mg, N-acetylcysteine 1000 mg
- Where
- Chile
- Volunteers
- 230 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.